Standardizing Safety Training for Nonpsychiatric Providers in Ketamine Therapy [0.03%]
氯胺酮治疗中非精神科提供者的安全培训标准流程
Ghulam Mustafa Memon
Ghulam Mustafa Memon
Optimizing Symptom Management in Patients With Posthepatectomy Liver Cancer Patients: A Qualitative Analysis of Self-Management Strategies and Their Impact on Clinical Outcomes [0.03%]
优化术后肝癌患者的症状管理：自我管理策略及其对临床结局影响的定性分析
Ru-Hui Yang,Di-Di Zhao,Wei-Zi Song
Ru-Hui Yang
Lina Obeid,Nezam Altorok,Nathaniel Gilbert
Lina Obeid
Erik M Wasowski
Erik M Wasowski
Global Clinical Trial Landscape of Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: Current Status and Future Trends [0.03%]
嵌合抗原受体T细胞治疗多发性骨髓瘤的全球临床试验格局：现状与未来趋势
Tongjie Shen,Zhaoqiang Xiang,Jian Liu
Tongjie Shen
Sheng Li,Ze Peng,Yu Qiu et al.
Sheng Li et al.
Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta-Analysis [0.03%]
胰高糖素样肽受体激动剂治疗特发性颅内压增高患者的疗效：系统评价和 meta 分析
Mohamed Saad Sayed,Basma Kamel,Noha S Shaban et al.
Mohamed Saad Sayed et al.
Pulmonary Arterial Pressure Monitoring of the Pulmonary Hemodynamics With Vericiguat in Heart Failure With Reduced Ejection Fraction [0.03%]
用于射血分数降低的心力衰竭患者肺循环血流动力学维立西呱药物浓度依赖性肺动脉压监测的研究
Andrew Xanthopoulos,Grigorios Giamouzis,Michail Papamichalis et al.
Andrew Xanthopoulos et al.
Comment on "Risk of Pericarditis Recurrence Associated With Rilonacept and NSAID/Colchicine Therapy After Initial Pericarditis Presentation: A Retrospective Real-World Comparative Risk Analysis With TriNetX" [0.03%]
对“使用伊拉那塞和非甾体抗炎药/秋水仙碱治疗初发心包炎后发生心包炎复发的风险：一项基于TriNetX的真实世界回顾性风险比较分析”的评论
Vidhya Parameswaran,Sheldon Wang,JoAnn Clair
Vidhya Parameswaran